LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Search

Bio-Techne Corp

Затворен

СекторЗдравеопазване

61.68 -2.87

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

61.07

Максимум

63.48

Ключови измерители

By Trading Economics

Приходи

56M

38M

Продажби

-30M

287M

P/E

Средно за сектора

130.122

80.03

EPS

0.53

Дивидентна доходност

0.5

Марж на печалбата

13.326

Служители

3,100

EBITDA

71M

78M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+4.99% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.50%

2.29%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

397M

9.9B

Предишно отваряне

64.55

Предишно затваряне

61.68

Настроения в новините

By Acuity

34%

66%

109 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Bio-Techne Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.11.2025 г., 22:36 ч. UTC

Печалби

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Bio-Techne Corp Прогноза

Ценова цел

By TipRanks

4.99% нагоре

12-месечна прогноза

Среден 66.71 USD  4.99%

Висок 70 USD

Нисък 60 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Bio-Techne Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

9 ratings

6

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

49.67 / 50.24Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Strong Bearish Evidence

Настроение

By Acuity

109 / 374 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat